Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
11:30am, Monday, 28'th Feb 2022 GlobeNewswire
Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
09:14am, Monday, 28'th Feb 2022
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st
2 Reasons Why Pfizer Might Crush Moderna in the mRNA Market. And 1 Reason Why Moderna May Stay Ahead.
11:15am, Thursday, 17'th Feb 2022 The Motley Fool
Pfizer's billion-dollar mRNA vaccine could be just the beginning.
Xpoint and Courtside Ventures Announce Investment Partnership
01:00pm, Wednesday, 16'th Feb 2022 Kwhen Finance
Pfizer (PFE) to Ride on COVID Jab & Pill in 2022: What Next?
02:00pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Pfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.
Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next?
02:00pm, Friday, 11'th Feb 2022 Marketing Sentinel
Beam Therapeutics Inc. (NASDAQ:BEAM)’s traded shares stood at 1.13 million during the last session. At the close of trading, the stock’s price was $64.60, to imply a decrease of -5.56% or -$3.8 in intraday trading. The BEAM share’s 52-week high remains $138.52, putting it -114.43% down since that peak but still an impressive 12.79% since … Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next? Read More »
2 Exciting Trends That Could Shape Healthcare's Future
11:00am, Thursday, 10'th Feb 2022 The Motley Fool
These underappreciated opportunities in healthcare are worth a closer look.
Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
11:30am, Wednesday, 09'th Feb 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that J
Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
11:30am, Wednesday, 09'th Feb 2022 GlobeNewswire
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.
Buy Pfizer Before The Smart Money Catches On To The Plot
11:25am, Wednesday, 09'th Feb 2022 Investing.comBeam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
06:30am, Wednesday, 09'th Feb 2022
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh
Here's What to Look For in Pfizer's Upcoming Earnings Report
11:15am, Tuesday, 25'th Jan 2022 The Motley Fool
Its COVID pill is practically guaranteed to be the biggest story.
Why Pfizer's Deal With Beam Therapeutics Is a Smart Move
04:28pm, Sunday, 23'rd Jan 2022 The Motley Fool
Pfizer gains access to Beam's gene-editing technology for three programs.
Moderna Is Betting on a New Way to Fight Cancer
11:58am, Sunday, 23'rd Jan 2022 The Motley Fool
The COVID-19 vaccine maker is jumping into CAR-M technology with its deal with Carisma Therapeutics.
Why Pfizer's Deal With Beam Therapeutics Is a Smart Move
11:28am, Sunday, 23'rd Jan 2022
Pfizer gains access to Beam's gene-editing technology for three programs.
